TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent.

Mark C Markowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.